Fennec Pharmaceuticals Inc (NASDAQ:FENC - Get Free Report) CEO Rosty Raykov sold 40,584 shares of Fennec Pharmaceuticals stock in a transaction dated Wednesday, April 3rd. The stock was sold at an average price of $10.78, for a total transaction of $437,495.52. Following the transaction, the chief executive officer now directly owns 276,054 shares of the company's stock, valued at $2,975,862.12. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website.
Fennec Pharmaceuticals Trading Down 2.0 %
Shares of Fennec Pharmaceuticals stock traded down $0.22 on Wednesday, hitting $10.77. 114,771 shares of the company traded hands, compared to its average volume of 108,943. The company has a market cap of $291.22 million, a PE ratio of -17.66 and a beta of 0.38. The stock's 50 day moving average price is $9.99 and its 200-day moving average price is $9.10. Fennec Pharmaceuticals Inc has a 52 week low of $6.30 and a 52 week high of $11.92.
Wall Street Analyst Weigh In
A number of brokerages recently issued reports on FENC. Craig Hallum raised their price target on Fennec Pharmaceuticals from $17.00 to $18.00 and gave the stock a "buy" rating in a research note on Monday, March 18th. Wedbush reiterated an "outperform" rating and issued a $16.00 target price on shares of Fennec Pharmaceuticals in a research note on Monday, March 18th.
Read Our Latest Report on FENC
Institutional Inflows and Outflows
Several institutional investors have recently bought and sold shares of FENC. Vanguard Group Inc. lifted its holdings in shares of Fennec Pharmaceuticals by 1,294.3% in the 4th quarter. Vanguard Group Inc. now owns 1,140,063 shares of the company's stock worth $12,792,000 after buying an additional 1,058,295 shares during the period. Goldman Sachs Group Inc. raised its holdings in shares of Fennec Pharmaceuticals by 78.8% in the fourth quarter. Goldman Sachs Group Inc. now owns 31,000 shares of the company's stock valued at $348,000 after acquiring an additional 13,664 shares in the last quarter. Barclays PLC lifted its stake in Fennec Pharmaceuticals by 624.7% in the fourth quarter. Barclays PLC now owns 25,075 shares of the company's stock worth $282,000 after acquiring an additional 21,615 shares during the period. Royal Bank of Canada grew its holdings in Fennec Pharmaceuticals by 21.1% during the 4th quarter. Royal Bank of Canada now owns 7,102 shares of the company's stock worth $79,000 after acquiring an additional 1,236 shares in the last quarter. Finally, Tower Research Capital LLC TRC grew its holdings in Fennec Pharmaceuticals by 107.3% during the 4th quarter. Tower Research Capital LLC TRC now owns 3,048 shares of the company's stock worth $34,000 after acquiring an additional 1,578 shares in the last quarter. 55.51% of the stock is currently owned by hedge funds and other institutional investors.
Fennec Pharmaceuticals Company Profile
(
Get Free Report)
Fennec Pharmaceuticals Inc, a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children.
Recommended Stories
Before you consider Fennec Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Fennec Pharmaceuticals wasn't on the list.
While Fennec Pharmaceuticals currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
